After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Puma Biotechnology Inc. (PBYI) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.02, or 0.71%, to $2.84. The Puma Biotechnology Inc. has recorded 3,986 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4).
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $2.82 and fluctuated between $2.9700 as its day high and $2.7850 as its day low. The current market capitalization of Puma Biotechnology Inc. is $160.06M. A total of 0.56 million shares were traded on the day, compared to an average of 362.00K shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, PBYI has seen 1 BUY and 5 SELL insider trades, representing the acquisition of 568,181 and the disposition of 51,993 shares. Over the last 12 months, there were 8 BUYs and 45 SELLs from insiders. Insiders purchased 2,522,295 shares during that period but sold 264,145.
In the most recent transaction, AUERBACH ALAN H sold 27,241 shares of PBYI for 4.18 per share on Jan 03. After the transaction, the President and CEO now owns 6,852,638 company shares. In a previous transaction on Jan 03, NOUGUES MAXIMO F sold 10,499 shares at 4.18 per share. PBYI shares that Chief Financial Officer owns now total 100,427.
Among the insiders who sold shares, Ludwig Jeffrey Jerome disposed of 6,568 shares on Jan 03 at a per-share price of $4.18. This resulted in the Chief Commercial Officer holding 58,057 shares of PBYI after the transaction. In another insider transaction, HUNT DOUGLAS M sold 4,225 shares at $4.18 per share on Jan 03. Company shares held by the insider now total 71,350.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for PBYI in the last 3 months, the mean price target is $4.75 with high estimates of $8.00 and low estimates of $2.00. In terms of 52-week highs and lows, PBYI has a high of $5.16 and a low of $1.60.
As of this writing, PBYI has an earnings estimate of $0.01 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of $0.07 per share and a lower estimate of -$0.08.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PBYI is Buy with a score of 3.33. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.
